Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Cash from Financing Activities: 2017-2019

Historic Cash from Financing Activities for Astria Therapeutics (ATXS) over the last 3 years, with Dec 2019 value amounting to $3.8 million.

  • Astria Therapeutics' Cash from Financing Activities rose 1026.78% to $3.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was $25.6 million, marking a year-over-year decrease of 42.16%. This contributed to the annual value of $157.2 million for FY2024, which is 77.83% up from last year.
  • Astria Therapeutics' Cash from Financing Activities amounted to $3.8 million in Q4 2019, which was up 287.67% from $973,000 recorded in Q3 2019.
  • Over the past 5 years, Astria Therapeutics' Cash from Financing Activities peaked at $38.5 million during Q2 2018, and registered a low of -$1.3 million during Q3 2018.
  • In the last 3 years, Astria Therapeutics' Cash from Financing Activities had a median value of $1.2 million in 2017 and averaged $6.2 million.
  • Within the past 5 years, the most significant YoY rise in Astria Therapeutics' Cash from Financing Activities was 1,083.01% (2018), while the steepest drop was 468.30% (2018).
  • Quarterly analysis of 3 years shows Astria Therapeutics' Cash from Financing Activities stood at $293,000 in 2017, then crashed by 238.91% to -$407,000 in 2018, then soared by 1,026.78% to $3.8 million in 2019.
  • Its Cash from Financing Activities was $3.8 million in Q4 2019, compared to $973,000 in Q3 2019 and $192,000 in Q2 2019.